[go: up one dir, main page]

JPS6245591A - Bicyclic dipeptide - Google Patents

Bicyclic dipeptide

Info

Publication number
JPS6245591A
JPS6245591A JP60184627A JP18462785A JPS6245591A JP S6245591 A JPS6245591 A JP S6245591A JP 60184627 A JP60184627 A JP 60184627A JP 18462785 A JP18462785 A JP 18462785A JP S6245591 A JPS6245591 A JP S6245591A
Authority
JP
Japan
Prior art keywords
thia
water
oxo
acid
azabicyclo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP60184627A
Other languages
Japanese (ja)
Inventor
Ukon Nagai
永井 右近
Kazunori Sato
一紀 佐藤
Rika Nakamura
中村 理果
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Kasei Corp
Original Assignee
Mitsubishi Kasei Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Kasei Corp filed Critical Mitsubishi Kasei Corp
Priority to JP60184627A priority Critical patent/JPS6245591A/en
Publication of JPS6245591A publication Critical patent/JPS6245591A/en
Pending legal-status Critical Current

Links

Landscapes

  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

NEW MATERIAL:A compound shown by the formula (R is t-butoxycarbonyl or fluoren-9-ylmethoxycarbonyl). EXAMPLE:2-Oxo-3-t-butoxycarbonylamino-7-thia-1-azabicyclo [ 4, 3, 0 ] nonane-9-car boxylic acid. USE:A reagent for analyzing active type conformation of physiologically active peptide. PREPARATION:For example, 2-oxo-3-amino-7-thia-1-azabicyclo[4,3,0]nonane-9- carboxylic acid is reacted with di-6-butyldicarbonate or 9- fluorenylmethylchloroformate, to give a compound shown by the formula I.

Description

【発明の詳細な説明】 (産業上の利用分野) 本発明は双環状ジペプチドに関する。[Detailed description of the invention] (Industrial application field) The present invention relates to bicyclic dipeptides.

(発明の構成) 本発明者等は、天然の生理活性ペプチドの活性型配座を
解明するための試架としての双環状ジペプチドの有用性
に着目し、種々の可能性につき検討した結果、新規な型
の配座制限類縁の合成にfi用な化合物を見いだし本発
明を達成したものである。
(Structure of the Invention) The present inventors focused on the usefulness of bicyclic dipeptides as a test bridge for elucidating the active conformation of natural physiologically active peptides, and as a result of examining various possibilities, discovered a novel The present invention was achieved by discovering a compound suitable for fi in the synthesis of a type of conformationally restricted analogue.

本発明の詳細な説明するに、本発明の双環状ジペプチド
としては、 (イ)[13式における Rが t−フ゛トキシカルボ
ニル基である、2−オキソ−3−L−ブトキンカル;1
テニルアミノ−7−チア−1−アザヒシク【コ[4,3
,01ノナン−9−)lルホン酸(以下Boc−[1T
D−011と略記する)及び、 (ロ)[l]式ζこおける Rがフルンrレンー9=イ
ルメトキシカル」てニル基である、2−オキソ−3−フ
ルオレン−7−イルメドキシカルポニルアミノー7−チ
アー1−アザビシクロ[L3,0コノナンー9−カルボ
ン酸(以下Fmoc−BTD−011と略記する)が挙
げられ、いずれも文献未載の新規な化合物である。
To explain the present invention in detail, the bicyclic dipeptide of the present invention includes (a) [2-oxo-3-L-butoxycarbonyl in which R in formula 13 is a t-phytoxycarbonyl group;
thenylamino-7-thia-1-azahishik [ko[4,3
,01nonane-9-)l sulfonic acid (hereinafter referred to as Boc-[1T
(abbreviated as D-011) and (b) [l] 2-oxo-3-fluoren-7-ylmedoxycarponyl, where R is a furun-9-ylmethoxycarnyl group Amino-7-thia-1-azabicyclo[L3,0 cononane-9-carboxylic acid (hereinafter abbreviated as Fmoc-BTD-011) is mentioned, and both are novel compounds that have not been described in any literature.

上記の化合物は、例えば、テトラヘトロンレターズ(T
etrahedron Letters ) 26巻、
N015、[i 47−654頁(1985年)に記載
された既λ11の化合物である、2−オキソ−3−フタ
リルイミド−7−チア−1−アザビシクロ[4,3,0
コノナン−9−カルホン酸(以下 Pt+t−BTD−
Ollと略記する)から容易に製造することができる。
The above compounds are, for example, tetrahetron letters (T
etrahedron Letters) Volume 26,
2-oxo-3-phthallimido-7-thia-1-azabicyclo[4,3,0
Cononane-9-carphonic acid (hereinafter referred to as Pt+t-BTD-
(abbreviated as Oll)).

即ち、前記(イ)の化合物(Boc−BTt’l−01
1)は、上記P h t、 −B T D −CI I
tを脱フタリル化することにより、2−オキソ−;3−
アミノ−7−チア−1−アザビシクロ[11,3,0]
]ノナンー9−カル;lン酸(以J:+1−81’D−
C1llと略記する)とし、次いてジーL−プチルシカ
ーボネ−1・で処理して+1−81’[l −011の
水素原子をL−ブトキシカル;i【ニル基で置換するこ
とにより得られる。
That is, the compound (A) (Boc-BTt'l-01
1) is the above P h t, -B T D -CI I
By defthalylating t, 2-oxo-;3-
Amino-7-thia-1-azabicyclo[11,3,0]
] Nonane-9-cal;
(abbreviated as C1ll), and then treated with di-L-butyl cicarbonate-1 to replace the hydrogen atom of +1-81'[l-011 with an L-butoxycar;i[nyl group.

また、前記([コ)の化合物(Fmoc−BTD−1)
It)は、」L記11BTD −011の化合物を9−
フルオレニルメチルクロロフォーメートで処理して、+
1−BTD −011の水素原子を9−フルオレニルメ
トキシカルボニル法−Ci社1委ずろことにより11ら
れる。
In addition, the compound (Fmoc-BTD-1) of ([co)]
It) is 9-
By treatment with fluorenyl methyl chloroformate, +
The hydrogen atom of 1-BTD-011 was converted to 11 by the 9-fluorenylmethoxycarbonyl method - Ci Co., Ltd. 1.

なお、前記既知物質のP b t −B T O−CI
 Itは、前記文献記載の周知の方法に従って、例えば
N−フタロイル−L−グルタミン酸蕉水物をりシクロヘ
キンルアミンの存在Fチオフェノールと反応させてr−
チオフェニルエステル体とし、次いてシアツメタンを用
いてと一チオフェニルーα−メチルエステル体とした後
、ラネーニッケルで還元してγ−力ルヒノール体とし、
これをピリジニウムクロロクロメートで酸化してγ−フ
ルデヒトーα−メチルエステル体となし、更にL−シス
ティンを縮合ざぜてチアゾリジン体とした後、加熱によ
り脱メタノールして製造することができる。
In addition, the known substance P b t -B T O-CI
It can be prepared by reacting, for example, N-phthaloyl-L-glutamic acid hydrate with thiophenol in the presence of cyclohexylamine according to well-known methods described in the literature.
A thiophenyl ester is obtained, and then a monothiophenyl-α-methyl ester is obtained using cyatsumethane, and then reduced with Raney nickel to obtain a γ-ruhinol compound,
It can be produced by oxidizing this with pyridinium chlorochromate to produce a γ-fludehyde-α-methyl ester, further condensing L-cysteine to produce a thiazolidine, and then removing methanol by heating.

(発明の効果) 本発明の双環状ジ・\ブチトは、天然の生理活性ペプチ
ドの活性型配座を解明ずろための試薬として有用である
。即ち、本発明の双環状ノベブチトは、ペプチドのβ−
ターン(製造を構成ずろアミノ酸配列の配座なそのまま
固定したような構造をとっているので、これを各種の活
性ペプチドにl(J 、77込むことにより、ペプチド
活性と立体配座(β−ターン構造)との関係について重
要な情報が得られ、生理活性ペプチドの解析用試埜とし
での出迎がI!I]持されろ。
(Effects of the Invention) The bicyclic di\butyto of the present invention is useful as a reagent for elucidating the active conformation of natural physiologically active peptides. That is, the bicyclic novelbutite of the present invention
Since it has a structure in which the conformation of the amino acid sequence is fixed without forming a turn (manufacturing), by incorporating this into various active peptides, the peptide activity and conformation (β-turn) can be determined. Important information can be obtained about the relationship between bioactive peptides (structures), and they can serve as samples for the analysis of bioactive peptides.

(実施例) 以F、本発明を実施例について更に詳細に説明ずろ。(Example) The present invention will now be described in more detail with reference to embodiments.

実施例 1 2−オギソー 3−1−フ′トキソカル月でニルアミノ
−7−チアーI−アザヒシクロ[4,3,01ノナン−
13−カルホンm (Boc−BTD−Otl )の製
造1.26 g(3,li +nM )の Pl+t−
BTU−Oll を 30m1のエタノーノし及U25
mlの水の混合イ(kに78解し、これ;こ0.!J 
ml (18mM )の抱水ヒトランンを 30111
のエタノールに、”dMした。′2I液を加え、2時間
加熱還流した後、減圧上溶媒を+;11: シ、残渣に
水35m1を加え、冷却下塩酸を滴加してHlt 2に
調節ずろ。生成した沈澱を遠心分離により除去し、−h
清を東め、沈澱は少量の水で数回洗7争して洗Iαは晶
7月の旧情に合する。
Example 1 2-Ogiso 3-1-F'toxocalmonylamino-7-thia I-azahicyclo[4,3,01nonane-
Preparation of 13-calfone m (Boc-BTD-Otl) 1.26 g (3,li + nM) of Pl + t-
BTU-Oll with 30m1 ethanol and U25
Mix ml of water a (78 is solved for k, this; this is 0.!J
ml (18mM) of human hydrated 30111
2I solution was added to ethanol at dM, and after heating under reflux for 2 hours, the solvent was removed under reduced pressure. Remove the formed precipitate by centrifugation, -h
After changing Qing to the east, the precipitate was washed several times with a small amount of water, and the wash Iα matched the old situation of the first month of July.

この上清lαを011−型陰イオン交換樹脂のカラム(
直径2.0 cm 、長さ 24(・m )に通ず。過
動のヒドラジンはカラムに吸石されずに、if出するの
でカラムを水洗後、IMの酢酸で溶出し、ニンヒドリン
反応性画分を集めて減圧下に溶媒を留去する。
This supernatant lα was transferred to a column of 011-type anion exchange resin (
It has a diameter of 2.0 cm and a length of 24 (・m). Hyperactive hydrazine is not absorbed into the column but is ejected, so after washing the column with water, it is eluted with IM acetic acid, the ninhydrin-reactive fraction is collected, and the solvent is distilled off under reduced pressure.

残渣に水を加えて減圧蒸留を 3回繰り返し、酢酸を完
全に留去する。残渣を熱水に、′7Jかし、エタノール
を加えて水冷し、生した結晶性成、殿を透過して 0.
03 g (2,9mM )の式 +1−BTD−1月
Iて示ざ21ろ化合物を得た。本物質の融点、比1度光
11!L及び7cζ分析値は次の通りであった。
Add water to the residue and repeat vacuum distillation three times to completely remove acetic acid. The residue was dissolved in hot water for 7J, ethanol was added, and the mixture was cooled with water.The resulting crystalline product was filtered through the precipitate.
03g (2,9mM) of the formula +1-BTD-1 was obtained. Melting point of this substance, ratio 1 degree light 11! The L and 7cζ analysis values were as follows.

融  点    : 300 ℃以」−比旋光度 : 
[α]p  275.8 = (c ” l +水 )
元素分析(1α: C11N    S 計算値:  44.4I35.59 12.95 14
.83分析i+cf :  44.13  5.39 
13.11 14.53上記に得た +1− B T 
D−011の0.(i3 z (2,9mM )を水 
12 ml及び INの水酸化ナトリウム液2.9ml
に溶解し、水冷後、これにジ−t−ブチルジカーボネー
ト 0.83 g< 3.8 mM )を 12 ml
のジオ八サンに溶解した溶イαを加えて室温で3.5時
間1★(′Fした(々、50m(の水を加え、水冷下 
10’l:クエン酸を滴加して pH]〜2に調節する
。次いてこれを酢酸エチル各30 mlで4回抽出し、
酢酸エチルjΔを集めて 10 Zクエン酸飽和食塩水
で洗?予後、市水fR酸ナトリウムを加えて乾燥ずろ。
Melting point: 300°C or higher - Specific optical rotation:
[α]p 275.8 = (c ” l + water)
Elemental analysis (1α: C11N S Calculated value: 44.4I35.59 12.95 14
.. 83 analysis i+cf: 44.13 5.39
13.11 14.53 +1- B T obtained above
0. of D-011. (i3z (2,9mM) in water
12 ml and 2.9 ml of IN sodium hydroxide solution
After cooling with water, add 12 ml of di-t-butyl dicarbonate (0.83 g < 3.8 mM) to the solution.
Add Solu α dissolved in Dio-Hatsan and heat at room temperature for 1★('F) for 3.5 hours.
10'L: Add citric acid dropwise to adjust pH to ~2. This was then extracted four times with 30 ml each of ethyl acetate.
Collect ethyl acetate jΔ and wash with 10 Z citric acid saturated saline? Prognosis, add city water fR sodium acid and dry.

乾燥剤を濾去し、I憲液を蒸発乾固した後、残清なメタ
ノールに溶解し、石油」−一テルを加えて沈澱させ、B
oc−BTD−Offて示される10生成物0.91g
を得た。これを酢酸エチルで再結晶してO,GII g
の精製物を11)だ。本物質の融点、比旋光度及U斤素
分析(直は次の通りであった。
After removing the desiccant by filtration and evaporating the I solution to dryness, it was dissolved in the residual methanol and precipitated by adding petroleum ester.
0.91 g of 10 product designated as oc-BTD-Off
I got it. This was recrystallized from ethyl acetate to obtain O, GII g
The purified product is 11). The melting point, specific optical rotation, and U-substance analysis of this substance were as follows.

融 点  : ItiO’Cて分解 比旋光度 ; [αで−218,4°(c=l、メタノ
ール) 元素分析値: CHN    S 計算値:  49.35   G、37  8.85 
10.13分析(lα:  49.21  6.26 
 8.77 10.20実施例2 2−オキソ−3−フルオレン−9′−イルメトギシカル
月てニルアミノ−7−チア−1−7ザビノクロ[4,3
,0コノナン−9−カルボン酸(Fmoc4TI−1]
 11 )の製造 実施例 1ζこ士3けろ II −B T U −01
1で示される化合物87 mg(0,4+nM )を1
0 =炭酸ナトリウム水rW 1(Xil、0 mlに
溶解して水冷し、撹rf下に 10(l mz (0,
4mM )の9−フルオレニルメチルクロロワ4−メ−
1・を含付する無水ジオキサンaノンα0.8 ml 
を滴加する。
Melting point: ItiO'C decomposition specific optical rotation: -218.4° at [α (c=l, methanol) Elemental analysis value: CHNS Calculated value: 49.35 G, 37 8.85
10.13 analysis (lα: 49.21 6.26
8.77 10.20 Example 2 2-oxo-3-fluoren-9'-ylmethoxycarmonylamino-7-thia-1-7zabinoclo[4,3
,0cononane-9-carboxylic acid (Fmoc4TI-1)
11) Manufacturing example of 1ζ 3-kero II-BTU-01
87 mg (0.4+nM) of the compound represented by 1 was added to 1
0 = Sodium carbonate water rW 1 (Xil, dissolved in 0 ml, cooled in water, stirred under rf 10 (l mz (0,
4mM) of 9-fluorenylmethylchloromethane (4mM)
0.8 ml of anhydrous dioxane anon α containing 1.
Add dropwise.

室温て;3時間反応後、反応混合物を20 mlの本水
中にゼ↑人し、次いて1°)られた透明な水溶瞼を水冷
下10 %クエン酸で酸性とした後、酢酸]−チル各2
0m1で3回抽出する。酢酸エチル層を集めて飽和食塩
水て洗ン争し、無水硫酸−)−トリウムで一夜間I′i
燥し、硫酸ナトリウノ、を繕去し1.iJ媒を留Jzし
た後アセトニトリルで再結晶してF m o (−81
’ D −(I IIて示される化合物71 mgをi
:)た。本物質の融点、比旋光度及び元素分析(lαは
次の通りてあ−)た。
After reacting for 3 hours at room temperature, the reaction mixture was poured into 20 ml of regular water, and then the transparent aqueous eyelid was acidified with 10% citric acid under water cooling, and then diluted with ethyl acetate. 2 each
Extract 3 times with 0ml. The ethyl acetate layer was collected, washed with saturated brine, and diluted with anhydrous sulfuric acid -)-thorium overnight.
Dry and remove the sodium sulfate.1. After distilling off the iJ medium, it was recrystallized with acetonitrile to obtain F m o (-81
'D-(III) 71 mg of the compound shown as
:)Ta. The melting point, specific rotation, and elemental analysis (lα is as follows) of this substance.

融 点:217〜2+9’( 比旋光度: [αコマ−147’ (C=1.[団「)
元素分析Il!′!: CHN    5
Melting point: 217 ~ 2 + 9' (Specific optical rotation: [α coma - 147' (C = 1. [Group ")
Elemental analysis Il! ′! : CHN 5

Claims (1)

【特許請求の範囲】[Claims] (1)遊離酸の形で、次式[1] ▲数式、化学式、表等があります▼−−−−[1] (式中Rはt−プトキシカルボニル基又はフルオレン−
9−イルメトキシカルボニル基を示す)で示される双環
状ジペプチド。
(1) In the form of free acid, the following formula [1] ▲ There are mathematical formulas, chemical formulas, tables, etc. ▼ ---- [1] (In the formula, R is a t-ptoxycarbonyl group or a fluorene-
9-ylmethoxycarbonyl group).
JP60184627A 1985-08-22 1985-08-22 Bicyclic dipeptide Pending JPS6245591A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP60184627A JPS6245591A (en) 1985-08-22 1985-08-22 Bicyclic dipeptide

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP60184627A JPS6245591A (en) 1985-08-22 1985-08-22 Bicyclic dipeptide

Publications (1)

Publication Number Publication Date
JPS6245591A true JPS6245591A (en) 1987-02-27

Family

ID=16156539

Family Applications (1)

Application Number Title Priority Date Filing Date
JP60184627A Pending JPS6245591A (en) 1985-08-22 1985-08-22 Bicyclic dipeptide

Country Status (1)

Country Link
JP (1) JPS6245591A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01209594A (en) * 1988-02-17 1989-08-23 Hitachi Ltd Image information processor

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01209594A (en) * 1988-02-17 1989-08-23 Hitachi Ltd Image information processor

Similar Documents

Publication Publication Date Title
Controulis et al. Chloramphenicol (Chloromycetin). 1 V. Synthesis
EP0097071B1 (en) Benzhydryl sulfinylacetamide derivatives and their therapeutical use
LU82613A1 (en) ANTIHYPERTENSIVE AMIDES
FR2483409A1 (en) 3-AMINO-2-HYDROXY BUTANOYLAMINOACETIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME
PT93876B (en) PROCESS FOR THE PREPARATION OF POLYAMINES AND USEFUL POLIPEPTIDEES AS ANTAGONISTS OF NEUROTRANSMITTERS OF AMINO ACID DRIVERS AND / OR AS BLOCKERS OF CALCIUM CHANNELS
NZ198826A (en) Bicyclic compounds and pharmaceutical compositions
EP0074309A1 (en) Process to increase the tolerance of opacifying products, and opacifying products so obtained
Saltza et al. Nystatin. IV. The Stereochemistry of Mycosamine
FR2468571A1 (en) 2,5-BIS (2,2,2-TRIFLUORETHOXY) -A, A, A-TRICHLORACETOPHENONE, PROCESS FOR PREPARATION AND APPLICATION THEREOF TO THE MANUFACTURE OF KNOWN DRUG
PT93218B (en) PROCESS FOR THE PREPARATION OF 2-AMINO-1,2,3,4-TETRA-IDRONAFALANS AND 3-AMINOCHROMANS SUBSTITUTED IN THE RING
AU3982599A (en) Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors
JPS6245591A (en) Bicyclic dipeptide
JPS62135491A (en) Aromatic sulfonate salt of proline derivative
FR2525215A1 (en) VASOPRESSIN ANALOGS
EP0241395A2 (en) Sweeteners derived from n-phenylguanidinoacetic and n-phenylethananamidinacetic acids, and compositions containing such sweeteners
SHAW et al. Preparation of m-Hydroxyphenyl-L-and D-Lactic Acids and Other Compounds Related to m-Tyrosine1
EP0289430B1 (en) Sweeteners derived from guanidinoacetic and ethanamidinoacetic acids, their uses and compositions containing these sweeteners
CH630893A5 (en) PROCESS FOR THE PREPARATION OF O- (2,6-DICHLOROANILINO) PHENYLACETAMIDES N, N-DISUBSTITUES.
EP0303545A2 (en) Process for the preparation of phenylethanolaminotetralines
Peterson et al. Some Reactions of α-Phthalimidonitriles Including Those Leading to the Synthesis of α-Aminoamidoximes and α-Aminothioamides1
Wolfrom et al. Acetylation of D-Mannose Phenylhydrazone
EP0073715A1 (en) Brominated compounds for use in opacifying products
FI68613C (en) FREQUENCY REQUIREMENT FOR THERAPEUTIC ACTIVATION WITH ACTIVE SAVING N-BENZYLAMINE SYROR
Schick et al. Synthesis of taurine and N-methyltaurine
Greenwood et al. Ozonolysis. V. Reaction of an Ozonide with the Isopropyl Grignard Reagent